Posner Christopher 4
4 · Cara Therapeutics, Inc. · Filed Apr 5, 2022
Insider Transaction Report
Form 4
Posner Christopher
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2022-04-04$12.67/sh−2,006$25,416→ 201,031 total
Footnotes (1)
- [F1]This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on May 28, 2021 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021, and does not represent a discretionary trade by the Reporting Person.